复方苦参注射液联合表柔比星治疗晚期胃癌的临床研究

目的研究复方苦参注射液联合注射用盐酸表柔比星治疗晚期胃癌的临床疗效。方法选取2015年12月—2017年12月富平县医院收治的120例晚期胃癌患者作为研究对象,随机将所有患者分为对照组和治疗组,每组各60例。对照组患者静脉滴注注射用盐酸表柔比星60 mg/m~2,根据患者血象可间隔21 d重复使用。治疗组患者在对照组治疗的基础上静脉滴注复方苦参注射液,20 mL溶于250 mL生理盐水中,1次/d。3周为1个疗程,两组患者均持续治疗2个疗程。观察两组患者的临床疗效,同时比较治疗前后两组Karnofsky(KPS)评分、免疫功能指标和不良反应。结果治疗后,对照组总有效率为58.33%,疾病控制率为70.00%,均分别显著低于治疗组的68.33%、88.33%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者KPS评分均显著升高,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组KPS评分显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者CD3+、CD4+、CD4+/CD8+水平均显著升高,CD8+水平显著降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组免疫功能指标水平均显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗期间,对照组和治疗组的不良反应发生率分别为16.70%、6.67%,两组比较差异具有统计学意义(P0.05)。结论复方苦参注射液联合注射用盐酸表柔比星治疗晚期胃癌具有较好的临床疗效,能够改善患者KPS评分和免疫功能,安全性较高,具有一定的临床推广应用价值。

Clinical study on Compound Kushen Injection combined with epirubicin in treatment of advanced gastric cancer

Objective To study the clinical effect of Compound Kushen Injection combined with Epirubicin Hydrochloride for injection in treatment of advanced gastric cancer. Methods Patients (120 cases) with advanced gastric cancer in Fuping County Hospital from December 2015 to December 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Epirubicin Hydrochloride for injection 60 mg/m², and reused for 21 d at intervals according to patients'' blood images. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. One course had 3 weeks, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies were evaluated, and the KPS scores, immune function indicators, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the total effective rate in the control group was 58.33%, and the disease control rate was 70.00%, which were significantly lower than 68.33% and 88.33% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, KPS scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, KPS scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, but the levels of CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the immune function indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). During the treatment, the adverse reaction rates in the control and treatment groups were 16.70% and 6.67%, respectively, and there were differences between two groups (P<0.05). Conclusion Compound Kushen Injection combined with Epirubicin Hydrochloride for injection has clinical curative effect in treatment of advanced gastric cancer, can improve the KPS scores and immune function of patients, with high safety, which has a certain clinical application value.